Cancer - Kidney(구연) (E-084) 신장암에서의 Sunitinib 과 Metformin 의 복합 치료 효과 ¹한양대학교 의과대학 비뇨의학교실 ²한양대학교 의생명공학전문대학원 임상의과학과 황현지¹·², 이지영¹, 홍성휘¹, 장은비¹·², 박성열¹, 문홍상¹, 윤영은¹* Sunitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, is a standard of care for first-line treatment of advanced renal-cell carcinoma. Metformin is known to be effective in the treatment of various cancers. We conducted this study to evaluate the anti-cancer effect of metformin combined with sunitinib. RCC cell line (A498) was used in this-study. Cell proliferation was measured by EZ-Cytox assay kit. Cell apoptosis and cell cycle arrest were analyzed by flow cytometry measurement through Annexin-V and PI staining. In addition, cell migration was measured by wound healing assay. Sunitinib and metformin showed concentration-dependent inhibitory effects on A498 cell. In combination treatment tests, sunitinib and metformin showed synergic effects (Fig. 1A). The flow cytometry analysis showed that the apoptotic of A498 cells were elevated after treatment sunitinib combination with metformin. Compared with the control group, sunitinib and metformin caused sub G0 cell cycle arrest. Next, to assess additional antitumorigenic effects of sunitinib and metformin, we performed a scratch wound-healing assay using A498 cells. As shown in Fig 2, sunitinib and metformin efficiently reduced the wound-healing capacity of the A498 cells, indication that two drug combination has antitumor efficacy in RCC cells. Metformin enhanced anti-proliferation, cell cycle arrest and anti-migration effect of sunitinib. Co-treatment metformin and sunitinib might be effective strategy for therapy. keywords : Sunitinib, Metformin, Renal cancer, Kidney cancer